

Table SI. Risk of psoriasis and psoriatic arthritis (PsA) according to regular use and duration of aspirin, NSAIDs, and acetaminophen with a 4-year lag between exposure and outcome in the Nurses' Health Study II (1991–2005)

	Non-regular users	Regular users	Duration			
			0	1–6 years	7–10 years	≥11 years
<i>Acetaminophen</i>						
Psoriasis						
No. of cases/person-years	333/645,244	144/198,458	276/541,890	114/193,870	36/47,790	13/7,577
Age-adjusted HR (95% CI)	1.00	1.21 (0.99, 1.47)	1.00	1.10 (0.88, 1.37)	1.21 (0.85, 1.73)	1.66 (0.94, 2.95)
Multivariate HR (95% CI) ^a	1.00	1.10 (0.90, 1.34)	1.00	1.00 (0.80, 1.25)	1.06 (0.74, 1.51)	1.41 (0.79, 2.50)
Multivariate HR (95% CI) ^b	1.00	1.08 (0.89, 1.32)	1.00	0.99 (0.79, 1.24)	1.04 (0.73, 1.49)	1.39 (0.78, 2.47)
PsA						
No. of cases/person-years	68/645,244	49/198,458	54/541,890	28/193,870	15/47,790	9/7,577
Age-adjusted HR (95% CI)	1.00	2.02 (1.39, 2.91)	1.00	1.40 (0.89, 2.22)	2.74 (1.51, 5.00)	6.39 (2.98, 13.7)
Multivariate HR (95% CI) ^a	1.00	1.67 (1.15, 2.42)	1.00	1.17 (0.74, 1.86)	2.09 (1.14, 3.83)	4.73 (2.19, 10.2)
Multivariate HR (95% CI) ^b	1.00	1.55 (1.06, 2.26)	1.00	1.09 (0.69, 1.74)	1.92 (1.04, 3.52)	4.28 (1.97, 9.30)
<i>NSAIDs</i>						
Psoriasis						
No. of cases/person-years	283/563,566	194/279,043	231/482,705	122/230,381	68/65,015	15/10,025
Age-adjusted HR (95% CI)	1.00	1.20 (0.99, 1.45)	1.00	1.03 (0.82, 1.29)	1.67 (1.24, 2.23)	1.55 (0.90, 2.67)
Multivariate HR (95% CI) ^a	1.00	1.06 (0.88, 1.28)	1.00	0.91 (0.72, 1.14)	1.34 (1.00, 1.81)	1.17 (0.67, 2.02)
Multivariate HR (95% CI) ^b	1.00	1.05 (0.86, 1.27)	1.00	0.89 (0.71, 1.13)	1.33 (0.98, 1.79)	1.15 (0.66, 2.00)
PsA						
No. of cases/person-years	51/563,566	66/279,043	37/482,705	36/230,381	25/65,015	7/10,025
Age-adjusted HR (95% CI)	1.00	2.26 (1.55, 3.30)	1.00	2.02 (1.25, 3.25)	4.26 (2.40, 7.56)	5.07 (2.10, 12.2)
Multivariate HR (95% CI) ^a	1.00	1.81 (1.23, 2.64)	1.00	1.58 (0.98, 2.55)	2.85 (1.60, 5.09)	3.06 (1.26, 7.44)
Multivariate HR (95% CI) ^b	1.00	1.71 (1.16, 2.52)	1.00	1.49 (0.92, 2.41)	2.68 (1.49, 4.79)	2.82 (1.16, 6.88)
<i>Aspirin</i>						
Psoriasis						
No. of cases/person-years	396/735,209	82/109,030	335/646,765	81/122,131	23/23,546	3/3,674
Age-adjusted HR (95% CI)	1.00	1.19 (0.94, 1.52)	1.00	1.17 (0.91, 1.50)	1.41 (0.92, 2.17)	0.73 (0.23, 2.30)
Multivariate HR (95% CI) ^a	1.00	1.06 (0.83, 1.34)	1.00	1.04 (0.81, 1.34)	1.24 (0.80, 1.91)	0.65 (0.21, 2.04)
Multivariate HR (95% CI) ^b	1.00	1.04 (0.82, 1.33)	1.00	1.03 (0.80, 1.32)	1.23 (0.79, 1.89)	0.64 (0.20, 2.03)
PsA						
No. of cases/person-years	95/735,209	23/109,030	77/646,765	22/122,131	8/23,546	1/3,674
Age-adjusted HR (95% CI)	1.00	1.29 (0.81, 2.04)	1.00	1.29 (0.80, 2.08)	1.91 (0.90, 4.02)	0.91 (0.12, 6.70)
Multivariate HR (95% CI) ^a	1.00	1.04 (0.65, 1.65)	1.00	1.06 (0.65, 1.72)	1.52 (0.72, 3.22)	0.76 (0.10, 5.57)
Multivariate HR (95% CI) ^b	1.00	0.98 (0.61, 1.56)	1.00	0.98 (0.60, 1.59)	1.42 (0.67, 3.02)	0.70 (0.09, 5.11)

^aMultivariate hazard ratios (HRs) were adjusted for age, follow-up interval, race, BMI, physical activity, smoking status, oral contraceptive use, postmenopausal hormones use, multi-vitamins use, cardiovascular disease, type 2 diabetes, hypertension, and hypercholesterolemia.

^bHRs were further adjusted for the other drugs (depending on the model) listed in the table.